CDKN2A and sarcoma: In other sarcomas, including gastrointestinal stromal tumors, loss of CDKN2A expression is associated with poor prognosis and a greater potential for metastatic disease.17,18,19 The biological meaning of CDKN2A/B loss in EHE requires further elucidation.